Lyell Immunopharma, Inc. (LYEL)
|52 Week Range||1.39-8.245|
|1y Target Est||-|
|DCF Unlevered||LYEL DCF ->|
|DCF Levered||LYEL LDCF ->|
|Debt / Equity||8.17%||Neutral|
Upgrades & Downgrades
Latest LYEL news
Lyell Immunopharma to Participate in Upcoming Investor Conferences
31 August 2023
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for...
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
26 August 2023
Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC,...
3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy?
14 June 2023
It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was the outcome of the June Fed meeting.
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
7 June 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for...
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
4 May 2023
Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.28 per share a year ago.
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
28 February 2023
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc...
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corn...
9 December 2022
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
4 November 2022
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies an...
5 October 2022
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies fo...
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade
12 September 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, t...